Drug Combo Approved for First-Line Treatment of Mesothelioma
Title: Drug Combo Approved for First-Line Treatment of MesotheliomaCategory: Health NewsCreated: 10/5/2020 12:00:00 AMLast Editorial Review: 10/6/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 6, 2020 Category: Cancer & Oncology Source Type: news

Drug Combo Approved for First - Line Treatment of Mesothelioma
Opdivo - Yervoy combination approved to treat adults with unresectable malignant pleural mesothelioma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 6, 2020 Category: Cancer & Oncology Tags: Oncology, Pharmacy, FDA Approvals, Source Type: news

Drug Combo Approved for First-Line Treatment of Mesothelioma
MONDAY, Oct. 5, 2020 -- On Friday, the U.S. Food and Drug Administration announced the approval of a drug combination for first-line treatment of unresectable malignant pleural mesothelioma (MPM) -- the first drug regimen to be approved for... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 5, 2020 Category: General Medicine Source Type: news

FDA Approves Opdivo, Yervoy Combination for Mesothelioma
The U.S. Food and Drug Administration has approved the immunotherapy combination of Opdivo and Yervoy for first-line treatment of unresectable malignant pleural mesothelioma. It was the first new drug regimen approved for mesothelioma in 16 years and only the second systemic therapy ever. The historic treatment approval for this cancer without a cure was the first since the FDA approved the chemotherapy combination of pemetrexed and cisplatin in 2004. “This marks the beginning of a new era for mesothelioma,” Dr. Bernardo Goulart, medical oncologist at Seattle Cancer Care Alliance, told The Mesothelioma Center at Asbest...
Source: Asbestos and Mesothelioma News - October 5, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

FDA Approves Opdivo, Yervoy Combination for Mesothelioma
The U.S. Food and Drug Administration has approved the immunotherapy combination of Opdivo and Yervoy for first-line treatment of unresectable malignant pleural mesothelioma. It was the first new drug regimen approved for mesothelioma in 16 years and only the second systemic therapy ever. The historic treatment approval for this cancer without a cure was the first since the FDA approved the chemotherapy combination of pemetrexed and cisplatin in 2004. “This marks the beginning of a new era for mesothelioma,” Dr. Bernardo Goulart, medical oncologist at Seattle Cancer Care Alliance, told The Mesothelioma Center at Asbest...
Source: Asbestos and Mesothelioma News - October 5, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

FDA OKs Combo Therapy for First-Line Mesothelioma Treatment FDA OKs Combo Therapy for First-Line Mesothelioma Treatment
Combination nivolumab and ipilimumab has now been approved as first-line treatment in mesothelioma and possibly a new standard of care.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 3, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma
PRINCETON, N.J.--(BUSINESS WIRE) October 2, 2020 -- Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 360 mg every three weeks plus Yervoy (ipilimumab) 1 mg/kg every six weeks (injections for intravenous use) was approved by... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 2, 2020 Category: Drugs & Pharmacology Source Type: news

FDA approves nivolumab and ipilimumab for unresectable malignant pleural mesothelioma
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 2, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

KCIC Report: Mesothelioma Lawsuits on the Rise in US
While the incidence of malignant mesothelioma in the United States continued its gradual decline, the tendency to sue for damages drastically increased in recent years, according to a KCIC study. Lawsuits filed by those stricken with the deadly asbestos-related cancer increased 65.7% from 2007 to 2017. Meanwhile, the overall incidence rate of mesothelioma dropped 16.2% during the same period. KCIC, a well-regarded consulting firm in Washington, D.C., that manages asbestos product liabilities, published the study of mesothelioma and asbestos litigation last week. Study author Megan Shockley, senior manager at KCIC, was unav...
Source: Asbestos and Mesothelioma News - September 29, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Gene Therapy Clinical Trial for Mesothelioma Moving Forward
This study will compare the effectiveness of the drug against a control group receiving only the gemcitabine and celecoxib. Patients have a one-in-two chance of being randomly assigned to either the adenovirus treatment or the control group. Adenovirus-delivered interferon Alpha-2b is designed as a second- or third-line treatment for patients who have failed in earlier regimens. Patients who previously had aggressive mesothelioma surgery but whose tumors have since progressed would be eligible to enroll. Success at the phase III level would mark the culmination of 20 years of researching and fine tuning gene therapy for us...
Source: Asbestos and Mesothelioma News - September 23, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Mesothelioma Trial to Test Cancer Vaccine with Immunotherapy
A research team at Oslo University Hospital in Norway has opened a mesothelioma clinical trial using the novel UV1 cancer vaccine alongside a promising immunotherapy combination. UV1 is a peptide-based vaccine designed to induce a specific T-cell response and increase the effectiveness of the immunotherapy drugs. This is the first time UV1 will be studied with mesothelioma cancer, but it already has shown safety and signs of efficacy when used on malignant melanoma, prostate cancer and lung cancer in studies worldwide. It will be used with the immunotherapy combination of nivolumab and ipilimumab, also known by brand names...
Source: Asbestos and Mesothelioma News - September 14, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Peer Review Finds EPA ’s Asbestos Risk Evaluation Flawed
The Science Advisory Committee on Chemicals found considerable failings and an underestimation of danger to the general public in a draft risk evaluation of asbestos submitted earlier this year by the U.S. Environmental Protection Agency. SACC, which serves as a scientific, peer-review mechanism for the EPA, released its recommendations last week in the ongoing governmental reevaluation of asbestos. This is the latest step in the amended Toxic Substances Control Act that requires the EPA to conduct evaluations on specific chemicals to determine whether they present unreasonable risk under conditions of use. The committee w...
Source: Asbestos and Mesothelioma News - September 2, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Georgia-Pacific Pledges $1B to Bestwall Asbestos Trust Fund
Georgia-Pacific has pledged $1 billion to fund an asbestos trust for bankrupt affiliate Bestwall LLC, clearing the path to a settlement of longstanding liability claims involving mesothelioma cancer. Bloomberg Law reported earlier this month that Georgia-Pacific made the financial commitment to advance a consensual resolution in the U.S. Bankruptcy Court for the Western District of North Carolina. Bestwall is a wallboard and joint compound product manufacturer that filed for Chapter 11 bankruptcy in 2017 with more than 62,000 pending claims involving asbestos. It was known earlier as Bestwall Gypsum Company, and was purcha...
Source: Asbestos and Mesothelioma News - August 25, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

New Lung Cancer Trial Could Benefit Mesothelioma Patients
Pharmaceutical giant Merck has teamed up with Novocure to test its cornerstone immunotherapy, pembrolizumab (Keytruda), alongside Tumor Treating Fields. The new phase II clinical research trial is focusing on non-small cell lung cancer and will enroll approximately 66 patients across the U.S. Keytruda, Merck’s anti-PD-1 therapy, works as a checkpoint inhibitor and allows the immune system to identify and attack cancer cells hiding within the PD-1 pathway. The FDA approved Keytruda for mesothelioma as the first immunotherapy treatment for the disease in 2020. Novocure, a global oncology company, has been developing Tum...
Source: Asbestos and Mesothelioma News - August 19, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news